A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Itacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.
- 23 Oct 2018 Planned End Date changed from 1 Jan 2021 to 1 Apr 2021.
- 23 Oct 2018 Planned primary completion date changed from 1 Nov 2020 to 1 Feb 2021.